BalenAMichelmoreK. What is polycystic ovary syndrome? Are national views important?Human reproduction. 2002;17(9):2219–2227.
2.
ClarkNMPodolskiAJBrooksED. Prevalence of polycystic ovary syndrome phenotypes using updated criteria for polycystic ovarian morphology: an assessment of over 100 consecutive women self-reporting features of polycystic ovary syndrome. Reprod Sci. 2014;21(8):1034–1043.
3.
LiaqatIJahanNKrikunGTaylorHS. Genetic polymorphisms in Pakistani women with polycystic ovary syndrome. Reprod Sci. 2015;22(3):347–357.
4.
LiuHYLiuJQMaiZXZengYT. A subpathway-based method of drug reposition for polycystic ovary syndrome. Reprod Sci. 2015;22(4):423–430.
5.
BianJShaoHLiuH. Efficacy of the levonorgestrel-releasing intrauterine system on IVF-ET outcomes in PCOS with simple endometrial hyperplasia. Reprod Sci. 2015;22(6):758–766.
6.
ErgenogluMYildirimNYildirimAG. Effects of resveratrol on ovarian morphology, plasma anti-Mullerian hormone, IGF-1 levels, and oxidative stress parameters in a rat model of polycystic ovary syndrome. Reprod Sci. 2015;22(8):942–947.
7.
SilvaAVde MeloASBarbozaRPMartinsWPFerrianiRAVieiraCS. Levonorgestrel-releasing intrauterine system for women with polycystic ovary syndrome: metabolic and clinical effects [published online January 4, 2016]. Reprod Sci. 2016. doi:10.1177/1933719115623648.
8.
HarrisonCLLombardCBMoranLJTeedeHJ. Exercise therapy in polycystic ovary 478 syndrome: a systematic review. Hum Reprod Update. 2011;17(2):171–183.
9.
OsthusIBSguraABerardinelliF. Telomere length and long-term endurance 503 exercise: does exercise training affect biological age? A pilot study. PloS one. 2012;7(12):e52769
10.
Miranda-FurtadoCLRamosFKKogureGS. A nonrandomized trial of progressive resistance training intervention in women with polycystic ovary syndrome and its implications in telomere content. Reprod Sci. 2016;23(5):644–654.
